Courier treatment of Alzheimer's disease, Phase 2 clinical results of innovative tau protein vaccine published

▎The content team editor of WuXi AppTec today, Axon Neuroscience announced that the complete results of the Phase 2 clinical trial of its tau protein vaccine AADvac1 for the treatment of Alzheimer's disease (AD) were published in the sub-published Nature Aging
.

The test results show that AADvac1 has excellent safety and stimulates a strong antibody response, which has a significant impact on neurodegeneration
.

Among AD patients confirmed by disease biomarkers, AADvac1 showed efficacy signals, which significantly delayed the decline of the patient's clinical and functional indicators
.

Neurofibrillary tangles (NFT) composed of pathological tau protein aggregation is one of the hallmarks of AD patients’ brains
.

Previous studies have shown that NFT is related to neuron death and brain atrophy, and the number and distribution of NFT in the brain are related to the disease progression and clinical symptoms of AD
.

AADvac1 is a tau protein vaccine designed to target the production and spread of pathological tau protein
.

The antibodies it stimulates can distinguish between normal and pathological tau proteins, thereby ensuring that only pathological tau proteins are targeted, which may have better efficacy and safety
.

In a 24-month randomized double-blind, placebo-controlled phase 2 clinical trial, AADvac1 reached the primary endpoint of the trial, showing good safety and tolerability
.

In addition, AADvac1 significantly reduced the accumulation of nerve fiber light chain (NfL)
.

NfL is an important biomarker of neurodegeneration, and AADvac1 reduces the level of NfL in the blood by 58% (P=0.
004)
.

Image source: 123RF In the subgroup of AD patients confirmed by AD biomarkers amyloid deposition and tau protein aggregation, AADvac1, compared with placebo, delayed the clinical decline detected by CDR-SB by 27% (p=0.
048) ), delaying the functional decline detected by ADCS-MCI-ADL by 30% (p=0.
039)
.

In this subgroup of patients, the level of NfL in the blood was reduced by 62% compared with the placebo group (p=0.
010)
.

Mr.
Michal Fresser, CEO of Axon Neuroscience, said: "Our Phase 2 clinical results demonstrate the potential of AADvac1 to change the course of the disease and support the advancement of this tau protein vaccine designed to prevent and treat AD to a critical clinical development stage
.

" Reference: [1] Nature Aging publishes phase II results for AADvac1, a first-in-man Alzheimer's tau vaccine developed by Axon Neuroscience.
Retrieved June 14, 2021, from https:// nature-aging-publishes-phase-ii-results-for-aadvac1-a-first-in-man-alzheimers-tau-vaccine-developed-by-axon-neuroscience-301311724.
html Note: This article aims to introduce medical and health research Progress is not a recommended treatment plan
.

If you need guidance on treatment plans, please go to a regular hospital for treatment
.